Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 5.44B | 5.38B | 3.71B | 2.95B | 2.79B |
Gross Profit | 4.56B | 1.50B | 977.00M | 714.80M | 653.00M |
EBITDA | 1.10B | 1.16B | 747.00M | 676.80M | 586.50M |
Net Income | 307.00M | 381.00M | 232.00M | 263.00M | 186.00M |
Balance Sheet | |||||
Total Assets | 10.55B | 11.13B | 11.92B | 4.32B | 5.84B |
Cash, Cash Equivalents and Short-Term Investments | 911.00M | 1.56B | 2.09B | 597.90M | 2.34B |
Total Debt | 4.11B | 4.73B | 5.40B | 1.93B | 3.40B |
Total Liabilities | 6.33B | 7.04B | 7.82B | 3.06B | 4.71B |
Stockholders Equity | 4.23B | 4.09B | 4.10B | 1.26B | 1.13B |
Cash Flow | |||||
Free Cash Flow | 463.00M | 526.00M | 410.00M | 403.30M | 391.70M |
Operating Cash Flow | 678.00M | 737.00M | 600.00M | 563.20M | 544.20M |
Investing Cash Flow | -373.00M | -416.00M | -1.20B | -441.10M | -327.00M |
Financing Cash Flow | -752.00M | -361.00M | 1.32B | -417.10M | 62.20M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | £7.26B | 20.64 | 29.71% | 3.34% | 1.14% | 17.74% | |
77 Outperform | £2.31B | 48.09 | 5.21% | 1.33% | 0.84% | -62.73% | |
76 Outperform | £556.51M | 16.32 | 12.12% | 2.83% | 10.34% | 33.59% | |
74 Outperform | £1.90B | 17.75 | 23.48% | 2.96% | 14.34% | -16.43% | |
67 Neutral | £358.74M | 38.19 | 4.01% | 2.00% | 6.90% | ― | |
66 Neutral | £9.08B | 35.51 | 5.93% | 2.05% | -1.58% | -34.64% | |
60 Neutral | kr42.58B | 13.50 | 1.95% | 2.32% | -0.60% | -20.68% |
Rentokil Initial reported a solid performance for the first half of 2025, with a 3.1% increase in group revenue and a strong free cash flow conversion rate of 93%. The company is seeing positive results from its sales and marketing initiatives in North America, particularly in organic lead generation, and plans to continue its integration efforts to achieve cost reductions and improve operating margins. Despite some declines in operating profit and basic EPS, the company’s strategic focus on organic growth and integration is expected to align with market expectations for the year.
The most recent analyst rating on (GB:RTO) stock is a Buy with a £520.00 price target. To see the full list of analyst forecasts on Rentokil Initial stock, see the GB:RTO Stock Forecast page.
Rentokil Initial PLC has announced a change in the nature of its holdings due to security lending, with GIC Private Limited now holding a 6.5% stake in the company. This adjustment in voting rights reflects a slight increase from previous holdings, indicating a strategic move by GIC to strengthen its influence within Rentokil Initial, potentially impacting the company’s governance and decision-making processes.
The most recent analyst rating on (GB:RTO) stock is a Buy with a £6.00 price target. To see the full list of analyst forecasts on Rentokil Initial stock, see the GB:RTO Stock Forecast page.
Rentokil Initial plc has announced that as of June 30, 2025, its issued share capital consists of 2,526,039,885 ordinary shares, each carrying one voting right. This update is crucial for shareholders to determine their interests in the company’s share capital under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:RTO) stock is a Buy with a £6.40 price target. To see the full list of analyst forecasts on Rentokil Initial stock, see the GB:RTO Stock Forecast page.
Rentokil Initial plc announced that Sally Johnson, a Non-Executive Director, purchased 3,567 ordinary shares of the company at a price of £3.5085 per share on June 2, 2025. This transaction, conducted on the London Stock Exchange, reflects a personal investment by a key managerial figure, potentially signaling confidence in the company’s future performance.
The most recent analyst rating on (GB:RTO) stock is a Buy with a £6.40 price target. To see the full list of analyst forecasts on Rentokil Initial stock, see the GB:RTO Stock Forecast page.
Rentokil Initial plc has announced the intended sale of its France Workwear business to H.I.G. Capital for approximately €410 million, with completion expected in Q4 2025. This move allows Rentokil Initial to streamline its operations, focusing more on its core pest control and hygiene & wellbeing sectors, enhancing capital efficiency, and improving cash flow. The transaction aligns with the company’s strategy to concentrate on high-growth markets and reduce capital expenditure, while the proceeds will be used for corporate purposes including deleveraging and investment in growth opportunities.
The most recent analyst rating on (GB:RTO) stock is a Buy with a £6.40 price target. To see the full list of analyst forecasts on Rentokil Initial stock, see the GB:RTO Stock Forecast page.
Rentokil Initial plc announced that its CEO, Andy Ransom, acquired 17,753 ordinary shares through the company’s Dividend Reinvestment Plan, with each share priced at £3.4706. This transaction, conducted on the London Stock Exchange, reflects a significant investment by a key executive, potentially indicating confidence in the company’s future performance and stability.
The most recent analyst rating on (GB:RTO) stock is a Buy with a £6.40 price target. To see the full list of analyst forecasts on Rentokil Initial stock, see the GB:RTO Stock Forecast page.